LANDSCAPE ASSESSMENT OF A MENA HEALTHCARE DATABASE FOR USE IN HEALTH ECONOMICS MODELING

Author(s)

Maskineh C1, Becker RV2, Kosremelli Asmar M3, Bekhazi H4, Sleilaty G5
1CCHO, Beirut, Lebanon, 2Russell Becker Consulting, Chicago, IL, USA, 3Institut Superieur de Sante Publique, Beirut, Lebanon, 4GlobeMed Lebanon, Sin El Fil, Lebanon, 5Institut Superieur de Sante Publique, Beirut, BA, Lebanon

OBJECTIVES: Real World Evidence (RWE) continues to be a fundamental tool that touches all stakeholders across the entire healthcare system, guides their decision, and contributes to generating useful economic modeling. The MENA region lacks data necessary for economic modeling. To fill the existing gap, Centre for Clinical Research and Health Outcomes (CCHO), GlobeMed and Higher Institute of Public Health (ISSP) of Saint-Joseph University (USJ) of Beirut are embarking to create a data warehouse reflecting the real world of treatment patterns and costs.

METHODS: A data mapping exercise was done to assess the capabilities of GlobeMed based longitudinal data as a source to cover data needs in health economic modeling. Data availability was assessed in a matrix framework. The inputs used were mapped into the following economic modeling categories: treatment patterns, epidemiology, patient health metrics, costs, resource use, and disease status.

RESULTS: GlobeMed database has over 22 years of longitudinal data. Its data claims are continuously updated and growing at 10% per year. The data covers 11 different markets in the Middle-Eastern and African territories: Lebanon, Ivory Coast, Syria, Saudi Arabia, Kuwait, Qatar, UAE, Bahrain, Jordan, Palestine, Egypt, and Nigeria. GlobeMed has over 800,000 unique patient submissions, including major therapeutic areas such as diabetes (1.2 million patients), oncology (114,000 patients) and respiratory patients (1.4 million patients) . Moreover, for inputs for costs, GlobeMed captures hospital, pharmacy and outpatient data. GlobeMed database can be used efficiently to generate patient treatment patterns, market opportunity assessment, medication adherence, orphan drugs & conditions, burden of illness, cost of resource utilization, and comparative effectiveness

CONCLUSIONS: GlobeMed database provides robust source of Real World Data. The collaboration of CCHO, GlobeMed, and ISSP (USJ) expertise will allow to fill data gaps and to leverage data-driven results in health economic modeling for the MENA region

Conference/Value in Health Info

2018-11, ISPOR Europe 2018, Barcelona, Spain

Value in Health, Vol. 21, S3 (October 2018)

Code

PHP265

Topic

Epidemiology & Public Health, Health Service Delivery & Process of Care, Health Technology Assessment

Topic Subcategory

Decision & Deliberative Processes, Health Care Research, Public Health

Disease

Multiple Diseases

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×